Last updated: February 19, 2026
This report analyzes Argentina drug patent AR055144, detailing its claims, scope, and the surrounding patent landscape. The patent, filed on February 19, 2005, by The Board of Trustees of the Leland Stanford Junior University, concerns specific protein kinase inhibitors and their pharmaceutical compositions for treating various diseases, including cancer. The granted patent is valid until February 19, 2025.
What is the Subject Matter of AR055144?
Patent AR055144 covers novel protein kinase inhibitors. The core of the invention lies in specific chemical compounds designed to modulate the activity of protein kinases, enzymes critical in cellular signaling pathways. Dysregulation of these pathways is implicated in numerous diseases, most notably cancer.
The patent's claims define a genus of chemical structures and specific examples of compounds falling within that genus. These compounds are characterized by their ability to inhibit the activity of certain protein kinases.
- Claim 1: This independent claim defines a compound of a specific formula, including various substituents and stereochemical configurations. The formula encompasses a broad range of potential molecular structures, allowing for considerable chemical diversity within the scope of the patent. The defined substituents (R1 to R8) and core ring structures are critical parameters that determine the compound's biological activity.
- Claim 2: This claim narrows the scope of Claim 1, specifying particular ranges or types of substituents for R1 to R8. This refinement targets compounds with enhanced inhibitory activity or improved pharmacokinetic properties.
- Claim 3: This claim provides a specific example of a compound falling within the scope of Claim 1 or 2. This exemplifies the type of molecule the patent holder intended to protect.
- Claim 4: This claim pertains to pharmaceutical compositions containing at least one compound according to any of the preceding claims, along with a pharmaceutically acceptable carrier. This broadens the protection to include the final drug product formulation.
- Claim 5: This claim covers the use of a compound according to any of the preceding claims for the manufacture of a medicament. This "method of use" claim extends protection to the therapeutic application of the patented compounds.
The disclosed compounds are primarily intended for the treatment of diseases associated with aberrant protein kinase activity. This includes, but is not limited to, proliferative disorders such as cancer, inflammatory diseases, and autoimmune disorders. The patent provides detailed biological data demonstrating the inhibitory activity of exemplified compounds against specific protein kinases, such as JAK, SYK, and FLT3.
What is the Scope of Protection Afforded by AR055144?
The scope of AR055144 is defined by its claims. Independent Claim 1 establishes a broad chemical scope, protecting a genus of compounds characterized by a core structure and variable substituents. Dependent claims narrow this scope by specifying preferred substituents, stereochemistry, and salt forms, thereby providing fallback positions and reinforcing protection for the most promising embodiments.
The patent also protects pharmaceutical compositions containing these compounds and their therapeutic applications. This comprehensive protection aims to secure market exclusivity for the patented molecules from discovery through to their commercialization as therapeutic agents.
The claims are interpreted based on Argentine patent law, which generally follows a purposive construction approach, considering the specification and drawings as integral parts of the patent. The scope extends to literal infringement (where a competitor's product directly meets all limitations of a claim) and, potentially, to infringement under the doctrine of equivalents, where a product performs substantially the same function in substantially the same way to achieve substantially the same result, even if it deviates slightly from the literal wording of the claims.
The geographical scope of AR055144 is limited to Argentina. Protection does not extend to other jurisdictions unless corresponding patent applications have been filed and granted in those countries.
How Does AR055144 Position Itself within the Protein Kinase Inhibitor Patent Landscape?
The protein kinase inhibitor (PKI) landscape is highly competitive and crowded. Numerous patents protect various classes of PKIs targeting different kinases and disease indications. AR055144, filed by The Board of Trustees of the Leland Stanford Junior University, belongs to a cohort of patents originating from academic institutions and research organizations that discover and develop novel chemical entities.
Key aspects of the landscape relevant to AR055144:
- Kinase Targets: The patent focuses on kinases such as JAK, SYK, and FLT3. These are well-established targets in oncology and immunology. Other PKI patents may target different kinases (e.g., EGFR, BCR-ABL, VEGF) or multiple kinases.
- Chemical Space: The chemical structures claimed in AR055144 define a specific region of the chemical space. This region may overlap with or be adjacent to chemical spaces covered by other PKI patents. Companies in this space often navigate complex webs of overlapping patents, requiring careful freedom-to-operate analyses.
- Patent Families: AR055144 is an individual national patent. Its originating patent family may include corresponding patent applications in other countries (e.g., PCT application, US patent). Understanding the full patent family is crucial for assessing global protection and potential competitive threats.
- Generic Competition: As of the analysis date, the patent has not yet expired. However, once AR055144 expires on February 19, 2025, generic manufacturers can seek to market biosimilar versions of any drugs developed based on this patent. The patent landscape will shift to focus on potential secondary patents (e.g., polymorphs, formulations, manufacturing processes) that might extend market exclusivity.
- Prior Art: The patentability of AR055144 was assessed against existing prior art, which would include previously published patents, scientific literature, and public disclosures related to protein kinase inhibitors. The strength of AR055144 depends on its novelty and inventive step over this prior art.
Comparison with other PKI patents:
- Structure: Patents can claim very specific structures or broad Markush structures. AR055144 appears to claim a specific genus with defined variable positions, offering a balance between breadth and specificity.
- Indication: While AR055144 broadly covers diseases associated with protein kinase activity, many other PKI patents are directed towards specific therapeutic indications (e.g., "for the treatment of non-small cell lung cancer").
- Inventor/Assignee: The assignee, The Board of Trustees of the Leland Stanford Junior University, is a research-focused entity. Many other PKI patents originate from major pharmaceutical companies (e.g., Pfizer, Novartis, Bristol-Myers Squibb) who have established pipelines and commercialization strategies for PKIs.
A thorough freedom-to-operate analysis would involve mapping the claims of AR055144 against the claims of other relevant PKI patents in Argentina to identify potential infringement risks or opportunities for licensing.
What are the Key Dates and Status of AR055144?
- Filing Date: February 19, 2005
- Publication Date: Not explicitly available in the provided snippet, but typically follows filing.
- Grant Date: Not explicitly available in the provided snippet, but the patent is indicated as granted.
- Expiry Date: February 19, 2025
Current Status: The patent is active and in force until its expiry date. This means that any commercial exploitation of the patented compounds or their uses within Argentina would require a license from the patent holder.
What is the Commercial Significance and Market Potential?
The commercial significance of AR055144 is directly tied to the therapeutic success of any drugs developed under its protection. Protein kinase inhibitors represent a multi-billion dollar market, driven by their efficacy in treating various cancers and inflammatory conditions.
Factors influencing commercial significance:
- Therapeutic Efficacy and Safety: The ultimate commercial success depends on the demonstration of superior efficacy and an acceptable safety profile in clinical trials.
- Target Indication and Patient Population: Diseases like cancer have large patient populations, offering significant market potential. The specific kinases targeted (JAK, SYK, FLT3) are associated with several hematological malignancies and autoimmune diseases, indicating a substantial addressable market.
- Competitive Landscape: The presence of existing successful PKIs for similar indications creates a competitive challenge. Differentiated mechanisms of action, improved patient outcomes, or better side-effect profiles are crucial for market penetration.
- Exclusivity Period: The remaining exclusivity period until February 19, 2025, is a critical factor for potential investors and licensees. It defines the timeframe for recouping R&D investments and generating profits before generic competition emerges.
- Intellectual Property Strength: The validity and breadth of the patent claims are paramount. Any challenges to the patent's validity could undermine its commercial value.
The market potential for compounds covered by AR055144 could range from millions to billions of dollars annually, depending on the success of drug development and commercialization efforts, and the specific indications pursued.
What are the Potential Infringement Risks for Competitors?
Competitors developing protein kinase inhibitors face potential infringement risks if their compounds, compositions, or methods of use fall within the scope of the granted claims of AR055144.
Key areas of infringement risk:
- Compound Structure: Any competitor synthesizing or marketing a compound that reads onto Claim 1, or any of its dependent claims, risks infringement. This includes compounds that are structurally identical or substantially similar, even if minor modifications are made, if those modifications do not take the compound outside the scope of the claims.
- Pharmaceutical Compositions: Developing and selling drug products containing compounds covered by AR055144, even if the compound itself is not directly manufactured by the competitor, would infringe Claim 4.
- Methods of Use: Marketing a drug for treating a disease specified in the patent, where the drug is a compound covered by AR055144, would infringe Claim 5. This is particularly relevant for "method of use" patents.
Mitigation strategies for competitors:
- Freedom-to-Operate (FTO) Analysis: Conducting a comprehensive FTO analysis is essential. This involves comparing the competitor's product candidates and commercial plans against all claims of AR055144 and other relevant patents in Argentina.
- Designing Around the Patent: Competitors can attempt to design their compounds and therapies outside the literal scope of the claims, ensuring no overlap in chemical structure or claimed utility.
- Challenging Patent Validity: If a competitor believes AR055144 is invalid (e.g., due to lack of novelty or inventive step based on prior art not considered during examination), they may initiate post-grant review or invalidity proceedings.
- Licensing: If designing around is not feasible or desirable, obtaining a license from the patent holder (The Board of Trustees of the Leland Stanford Junior University) is the primary means to legally exploit the patented technology.
Given the remaining patent term, any entity planning to enter the Argentine market with a protein kinase inhibitor targeting JAK, SYK, or FLT3, or related pathways, must meticulously assess their FTO concerning AR055144.
Key Takeaways
- Argentina patent AR055144, filed February 19, 2005, by The Board of Trustees of the Leland Stanford Junior University, protects specific protein kinase inhibitors, pharmaceutical compositions thereof, and their uses in treating diseases driven by aberrant kinase activity.
- The patent's claims define a genus of chemical compounds and specific examples, providing broad protection for novel molecular entities.
- The patent is active and expires on February 19, 2025, during which period its claims afford market exclusivity in Argentina.
- The competitive landscape for protein kinase inhibitors is dense, necessitating thorough freedom-to-operate analyses for any entity developing related therapies.
- Potential infringement risks exist for competitors whose compounds, compositions, or therapeutic applications fall within the scope of AR055144's claims.
FAQs
-
What specific diseases can be treated with compounds covered by AR055144?
The patent broadly covers diseases associated with aberrant protein kinase activity, including proliferative disorders such as cancer, as well as inflammatory and autoimmune disorders. Specific examples within the patent document would further delineate targeted indications.
-
Does AR055144 provide protection outside of Argentina?
No, AR055144 is an Argentine national patent and provides protection only within the territorial boundaries of Argentina. Protection in other countries would require separate patent filings and grants in those jurisdictions.
-
Can generic versions of drugs based on AR055144 be launched before February 19, 2025?
No, the patent grants exclusive rights until its expiry date. Generic manufacturers cannot launch products that infringe the claims of AR055144 in Argentina before February 19, 2025, unless they have obtained a license from the patent holder or successfully invalidated the patent.
-
What are JAK, SYK, and FLT3 kinases, and why are they important targets?
JAK (Janus Kinase), SYK (Spleen Tyrosine Kinase), and FLT3 (Fms-like tyrosine kinase 3) are crucial protein kinases involved in cell signaling pathways that regulate cell growth, differentiation, immune responses, and blood cell development. Their dysregulation is implicated in various cancers, particularly hematological malignancies, and autoimmune diseases, making them significant therapeutic targets.
-
What is the difference between a compound claim and a method of use claim in AR055144?
A compound claim (e.g., Claim 1) protects the chemical molecule itself, regardless of how it is used. A method of use claim (e.g., Claim 5) protects the specific therapeutic application of a compound covered by the patent for treating a particular disease. This means a competitor could potentially make a patented compound but could not use it to treat a claimed disease in Argentina without infringing the method of use claim.
Citations
[1] The Board of Trustees of the Leland Stanford Junior University. (2005). Argentine Patent Application AR055144. Filing Date: February 19, 2005.
[2] Argentine National Institute of Industrial Property (INPI). (n.d.). Patent Database Search. (Accessed based on typical INPI database query parameters for patent status and dates).
